Free Trial

Zevra Therapeutics (NASDAQ:ZVRA) Shares Climb 6.3% - What's Next?

Zevra Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) was up 6.3% during trading on Monday. The company traded as high as $9.79 and last traded at $9.65. 343,567 shares changed hands during mid-day trading, a decline of 72% from the average session volume of 1,225,672 shares. The stock had previously closed at $9.08.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on ZVRA shares. Citigroup restated an "outperform" rating on shares of Zevra Therapeutics in a research report on Thursday, August 6th. Cantor Fitzgerald reduced their target price on Zevra Therapeutics from $25.00 to $19.00 and set an "overweight" rating on the stock in a report on Friday. HC Wainwright reissued a "buy" rating and set a $26.00 target price on shares of Zevra Therapeutics in a research report on Thursday, August 20th. William Blair upgraded shares of Zevra Therapeutics to a "strong-buy" rating in a report on Wednesday, September 23rd. Finally, Canaccord Genuity Group dropped their price target on shares of Zevra Therapeutics from $29.00 to $20.00 and set a "buy" rating on the stock in a research report on Monday, July 27th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $23.86.

Read Our Latest Analysis on ZVRA

Zevra Therapeutics Trading Up 3.3%

The company has a market cap of $558.16 million, a price-to-earnings ratio of 7.87 and a beta of 1.01. The firm's 50-day moving average price is $10.99 and its 200 day moving average price is $10.83.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last released its earnings results on Tuesday, November 3rd. The company reported $0.26 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.16 by $0.10. The company had revenue of $37.76 million for the quarter, compared to the consensus estimate of $37.08 million. Zevra Therapeutics had a net margin of 52.80% and a return on equity of 54.64%. Analysts forecast that Zevra Therapeutics, Inc. will post 0.88 earnings per share for the current fiscal year.

Insider Buying and Selling at Zevra Therapeutics

In other news, CEO Neil McFarlane sold 20,000 shares of the stock in a transaction dated Monday, October 12th. The shares were sold at an average price of $11.25, for a total transaction of $225,000.00. Following the transaction, the chief executive officer owned 417,225 shares of the company's stock, valued at $4,693,781.25. This represents a 4.57% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 3.70% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Integrated Wealth Concepts LLC acquired a new position in shares of Zevra Therapeutics during the second quarter worth approximately $28,000. Fulcrum Asset Management LLP bought a new stake in Zevra Therapeutics during the 3rd quarter valued at $31,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in Zevra Therapeutics during the 3rd quarter valued at $33,000. State of Alaska Department of Revenue bought a new stake in Zevra Therapeutics during the 3rd quarter valued at $44,000. Finally, State of Wyoming acquired a new position in Zevra Therapeutics during the third quarter worth $81,000. 35.03% of the stock is owned by institutional investors and hedge funds.

About Zevra Therapeutics

(Get Free Report)

Zevra Therapeutics, Inc. is a U.S.-based biopharmaceutical company focused on developing and commercializing treatments for rare diseases. Its work includes research and development as well as bringing therapies to patients with limited treatment options. The company's products include MIPLYFFA (arimoclomol), approved in the United States for neurological manifestations of Niemann-Pick disease type C, and OLPRUVA (sodium phenylbutyrate), a treatment for certain urea cycle disorders. Zevra also advances investigational therapies for rare and complex conditions.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Zevra Therapeutics Right Now?

Before you consider Zevra Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zevra Therapeutics wasn't on the list.

While Zevra Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines